Treatment of Histologic Transformation

Link to article at PubMed

Hematol Oncol Clin North Am. 2020 Aug;34(4):785-794. doi: 10.1016/j.hoc.2020.03.001. Epub 2020 May 5.

ABSTRACT

Histologic transformation from follicular lymphoma to aggressive lymphoma historically had a poor prognosis. Routine use of anti-CD20 antibody rituximab has changed the landscape of follicular lymphoma (FL) such that outcomes are improved in select patients, similar to de-novo diffuse large B-cell lymphoma. Several biological and clinical biomarkers can predict risk of transformation, and ongoing research is improving understanding of the biology surrounding the transformation process. This review provides an overview of risk factors, prognosis, and treatment of histologic transformation of FL.

PMID:32586581 | DOI:10.1016/j.hoc.2020.03.001

Leave a Reply

Your email address will not be published.